I disagree. I think any price sub 2.2c and you will see a lot of buyers come in to snap up shares considering the assets, IP and pipeline of prospective positive developments this company is capable of delivering, especially now after the recent acquisitions. IMO it will be a rare opportunity to take up positions in this company at favourable prices before a trend reversal, assuming the forthcoming announcements yield positive news on the clinical trials front.
Potentially 3b comp valued less 100m, page-39
-
- There are more pages in this discussion • 19 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
